Walter M. Stadler to Drug Administration Schedule
This is a "connection" page, showing publications Walter M. Stadler has written about Drug Administration Schedule.
Connection Strength
0.801
-
Effective therapy for metastatic renal cancer, whither to now. J Clin Oncol. 2009 Aug 01; 27(22):3573-4.
Score: 0.073
-
A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. Cancer. 2006 Sep 15; 107(6):1273-9.
Score: 0.061
-
A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin Genitourin Cancer. 2006 Jun; 5(1):57-60.
Score: 0.059
-
Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. J Clin Oncol. 2004 Jan 01; 22(1):115-9.
Score: 0.050
-
A G2/M growth arrest response to low-dose intermittent H2O2 in normal uroepithelial cells. Int J Oncol. 2000 Sep; 17(3):425-32.
Score: 0.040
-
Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol. 2000 Jun; 18(12):2419-26.
Score: 0.039
-
A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. Cancer. 2020 05 15; 126(10):2146-2152.
Score: 0.038
-
Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. J Clin Oncol. 2000 Jan; 18(2):371-5.
Score: 0.038
-
Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. Cancer. 2019 06 01; 125(11):1830-1836.
Score: 0.036
-
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016 May 14; 387(10032):2008-16.
Score: 0.029
-
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol. 2016 Mar; 17(3):378-388.
Score: 0.029
-
Low-dose interleukin-2 in the treatment of metastatic renal-cell carcinoma. Semin Oncol. 1995 Feb; 22(1):67-73.
Score: 0.027
-
Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. Eur J Cancer. 2014 Dec; 50(18):3145-52.
Score: 0.027
-
Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer. 2014 Mar 01; 120(5):692-701.
Score: 0.025
-
Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest New Drugs. 2012 Feb; 30(1):382-6.
Score: 0.020
-
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010 May 01; 28(13):2137-43.
Score: 0.019
-
Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. Cancer. 2009 Sep 15; 115(18):4110-7.
Score: 0.019
-
MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure. Invest New Drugs. 2009 Aug; 27(4):379-86.
Score: 0.018
-
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol. 2008 Aug 01; 26(22):3743-8.
Score: 0.017
-
Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma. Cancer. 2008 Jul 01; 113(1):72-7.
Score: 0.017
-
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006 Jun 01; 24(16):2505-12.
Score: 0.015
-
A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res. 2006 Mar 01; 12(5):1556-63.
Score: 0.015
-
A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer. Am J Clin Oncol. 2005 Apr; 28(2):109-13.
Score: 0.014
-
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004 Mar 01; 22(5):909-18.
Score: 0.013
-
A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma. Cancer. 2004 Jan 01; 100(1):65-71.
Score: 0.013
-
Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol. 2002 Nov 15; 20(22):4478-84.
Score: 0.012
-
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies. Cancer. 2001 Sep 15; 92(6):1567-76.
Score: 0.011
-
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin Cancer Res. 2001 May; 7(5):1214-20.
Score: 0.010
-
Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrations. Cancer Chemother Pharmacol. 2000; 45(6):489-94.
Score: 0.010
-
Study of cohort-specific consent and patient control in phase I cancer trials. J Clin Oncol. 1998 Jul; 16(7):2305-12.
Score: 0.009